Papyrus Advances TBS Samples and Expands Pulp Capacity

Second TBS Sample Batch Moves Through Acceptance Process

Papyrus Australia Ltd (ASX:PPY) has completed production of a second batch of paperboard samples for TBS Mining Solutions, giving its commercialisation program another step to clear before supply can begin. The run followed a revised milestone timetable agreed with TBS, a subsidiary of Aquirian Limited (ASX:AQN), to allow additional samples to be produced and tested.

The company said the second production-scale trial incorporated lessons from the initial run and involved optimisation work with manufacturing partners on converting its pulp into paperboard. That is progress, but not acceptance: Papyrus has not reported that TBS testing is complete or that commercial supply has commenced.

Adelaide Facility Expands Ahead of Initial Production

Papyrus also increased pulp production capacity at its Adelaide Rapid Prototyping and R&D Facility. The expanded capability is intended to support initial commercial production requirements for TBS boards while allowing the company to continue smaller-scale product development and research.

Alongside the operational work, Papyrus filed an Australian provisional patent application on 21 August for a method of manufacturing moulded fibre products with fibre reinforcement elements. The company described possible applications including structural and lightweight products such as unmanned aerial vehicle airframes, but expressly cautioned that those possibilities remain subject to further research, testing, prototyping and commercial validation.

New Funding Extends Capacity but Not Financial Certainty

Papyrus secured a further $500,000 through four unsecured loan agreements with professional and sophisticated investors during August. The funds are earmarked for the TBS contract, commercialisation activities and working capital. Conversion of the outstanding loans, including accrued interest, into Tranche 2 unsecured convertible notes will require shareholder approval at the 2026 annual general meeting.

The August cash flow statement recorded $375,000 in proceeds from borrowings, while the company ended the month with $421,000 in cash and $572,000 of unused financing facilities. Net operating cash outflow was $204,000, and Papyrus calculated its estimated funding available at 4.87 months. The headline cash figure also includes $214,000 held in Egypt by its wholly owned subsidiary that is restricted, making the quality and availability of liquidity an important detail alongside the reported balance.

Commercialisation Progress Meets a Near-Term Funding Test

Papyrus said it expects to maintain its current level of operating cash outflow and continue operations through further capital raising, progress on its commercialisation roadmap and delivery of a previously announced contract. Those statements describe the company’s basis for continuing as a going concern, rather than evidence that the funding requirement has been resolved.

The next meaningful evidence will come from TBS acceptance of the additional samples and any confirmation that the revised development timetable has translated into commercial supply. Until then, Papyrus is funding a still-unfinished product pathway with borrowings and a cash position that the company itself estimates will cover less than six months of operations.